Background: Reperfusion therapy is known to improve prognosis and limit
INTRODUCTION
Acute myocardial infarction (AMI) is the most severe manifestation of coronary artery disease [1] . Prompt recanalization of the culprit vessel and restoration of blood flow to the myocardium are the main therapeutic goals in AMI. Currently, percutaneous coronary intervention (PCI) and thrombolytic therapy are used for effective reperfusion, improving blood flow and preventing recurrent ischemia [2, 3] .
Nevertheless, studies have suggested that there is a great variation in the provision of 3 reperfusion therapy [5] . Although the rate of early reperfusion therapy for myocardial infarction (MI) has reached a fairly high level in many developed countries. In developing countries, such as China, during the decade 2001-2011, outcomes of in-hospital treatment for ST-segment elevation MI (STEMI) patients have not improved significantly: the proportion of patients receiving reperfusion therapy has not increased. The treatment of STEMI patients is still significantly delayed, and more than half of STEMI patients miss the opportunity of reperfusion therapy due to delayed consultation [4] .
Antiplatelet drugs have been the cornerstone of secondary prevention in patients with coronary heart disease, and these agents have significantly reduced the mortality and have improved the prognosis. Double antiplatelet therapy (DAPT) is a pivotal treatment strategy for patients with AMI and has been recommended in many guidelines [2, 3, 6] . In recent years, assessment of the most appropriate timing for initiating the administration of antiplatelet drugs has been focused upon on with great interest. Many studies [7, 8] have shown the administration of antiplatelet drugs prior to PCI to be beneficial in patients with MI. Brener et al. [8] suggested that acetylsalicylic acid (ASA) pretreatment reduced the mortality at 30 days, especially in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS).
However, the benefits of pretreatment with antiplatelet drugs in patients with MI who do not receive reperfusion therapy are not clear. The aim of this study was to evaluate the effects of pretreatment with antiplatelet drugs on cardiac function after MI in a mouse MI model.
METHODS

Reagents and materials
Apyrase and prostaglandin E1 were purchased from Sigma-Aldrich Corporation 
Experimental design
The mice were randomly divided into five groups: (1) sham operation groupa suture was passed under the left anterior descending (LAD) coronary artery without ligation; (2) control group -MI was induced using the model described below, and the same vehicle was administered intragastrically; (3) post-treatment group -after MI induction, mice were given ASA (15 mg/kg), clopidogrel (11 mg/kg), ticagrelor (27 mg/kg), or prasugrel (1.5 mg/kg) by intragastric administration for 7 days; (4) pre-treatment group -before MI induction, ASA (15 mg/kg), clopidogrel (11 mg/kg), ticagrelor (27 mg/kg), or prasugrel (1.5 mg/kg) was orally administered to the mice for 7 days; (5) pre-and post-treatment group -for 7 days prior to and for 7 days after MI induction, ASA (15 mg/kg), clopidogrel (11 mg/kg), ticagrelor (27 mg/kg), 5 or prasugrel (1.5 mg/kg) was orally administered to the mice. In each group, 10 mice were treated with each of the drugs. The drugs were dissolved in normal saline. For each drug, the dose selection was based on the human clinical dosage: ASA (100 mg/60 kg), clopidogrel (75 mg/60 kg), ticagrelor (90 mg/60 kg), or prasugrel (10 mg/60 kg).
Myocardial infarction model
The mice were housed in a temperature-controlled environment with 12-h light/12-h dark cycles. MI was induced by permanent ligation of the LAD coronary artery, as described previously [9] . Eight-week-old mice were anesthetized by isoflurane inhalation. A rodent ventilator (Model 683, Harvard Apparatus, Inc., Holliston, MA, USA) was used with 65% oxygen during the surgical procedure. The animals were kept warm using heat lamps and heating pads. A left thoracotomy was performed in the fourth intercostal space. The heart of the mouse was exposed, and the LAD coronary artery was ligated, 2 mm from its ostial origin, with a 7-0 silk suture. Regional ischemia was confirmed by changes in the electrocardiogram (ST-segment elevation). A sham operation involved the same procedure, but a suture was passed under the LAD coronary artery without ligation.
Echocardiography
Echocardiography was performed using a Vevo 770 high-resolution imaging system at day 7 after MI induction as described previously [9] . The animals were anesthetized with isoflurane inhalation and placed in the supine position. The chest was shaved, and parasternal short-and long-axis views were used to obtain two-dimensional and M-mode images by echocardiography. At least 10 independent cardiac cycles were obtained for each measurement.
Masson's trichrome staining
The hearts were harvested at the end of the study and were perfused and fixed in 
Platelet preparation and aggregation
The washed platelets from wild-type mice were prepared as previously described [10] . These were adjusted to a density of 3 × 10 8 platelets/mL. The platelets were evaluated for aggregation with reactive oxygen species (ROS)-induced stress with thrombin. They were incubated with H2O2 (200 μmol/mL) for 3 min and then with ASA, the clopidogrel active metabolite, ticagrelor, or the prasugrel active metabolite for 3 min, and platelet aggregation was induced by thrombin.
Immunohistochemistry
Myocardial tissue was fixed in formalin for 24 h and then embedded in paraffin.
The parasternal short-axis sections were cut into 4 μm-thick slices. To quench the endogenous peroxidase activity the sections were deparaffinized and incubated with 3% hydrogen peroxide for 10 min at room temperature. The sections were layered with the anti-CD45 polyclonal antibody (1:500) at 4°C overnight and were subsequently 
Statistical analysis
Data are presented as means ± standard error. The statistical significance of 7 multiple treatments was determined using the GraphPad Prism Software Version 5.9
(San Diego, CA, USA) by the Student t-test or ANOVA (one-way and two-way),
followed by either a Newman-Keuls or Bonferroni post hoc test, when appropriate.
The values of p < 0.05 were considered statistically significant.
RESULTS
ASA, clopidogrel, ticagrelor, and prasugrel pretreatment improves cardiac function after MI
The representative M-mode echocardiograms, performed on day 7 after MI, from each group are shown in Figure 1A . Compared with the control group, significant changes in left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) were observed in the pre-treatment, pre-and post-treatment, and post-treatment groups. In the groups that were pretreated with ASA, clopidogrel, ticagrelor, or prasugrel, the cardiac function was significantly preserved compared to that in the post-treatment and control groups (Fig. 1B-I ). The differences between the control and pre-treatment groups were statistically significant (p < 0.01). Among the four drugs, clopidogrel was less effective in improving the mouse cardiac LVEF and LVFS compared with ASA, ticagrelor, and prasugrel in the pre-treatment, pre-and post-treatment, and post-treatment groups (Fig. 1J , K); significant differences (p < 0.05) were observed in these cases.
ASA, clopidogrel, ticagrelor and prasugrel pretreatment decreases cardiac fibrosis after MI
After MI, the initial reparative fibrosis is crucial in preventing the rupture of the ventricular wall, but an exaggerated fibrotic response is detrimental and results in progressive impairment of cardiac function [11] . Cardiac fibrosis with the Masson trichrome staining on day 7 after MI was evaluated. Representative images of fibrotic areas in the different groups are shown in Figure 2A . Compared with the control group, treatment with ASA, clopidogrel, ticagrelor, and prasugrel decreased cardiac 8 fibrosis. It was more significantly reduced in the group pretreated with antiplatelet drugs than in the posttreatment and control groups ( Fig. 2B-E ). The differences in cardiac fibrosis between the control and drug treatment groups were statistically significant (p < 0.05). In a comparison of different antiplatelet drugs, the clopidogrel group had a larger fibrotic area after MI compared with that in the ASA, ticagrelor or prasugrel group (Fig. 2F , p < 0.05); these differences were statistically significant. 
ASA
ASA, clopidogrel, ticagrelor, and prasugrel inhibit platelet aggregation in response to oxidative stress
Platelets are activated soon after an MI, and their activation depends on the duration of coronary occlusion and the extent of myocardial injury. Platelet aggregation was measured using washed mouse platelets stimulated with thrombin.
In the control group, thrombin-induced platelet aggregation was increased with 9 exposure to H2O2. Thrombin-induced platelet aggregation in the presence of H2O2 was significantly inhibited by ASA, clopidogrel, ticagrelor, and prasugrel (Fig. 4 ).
Ticagrelor and prasugrel were used at lower doses than ASA and clopidogrel; nonetheless, they demonstrated similar inhibitory effects on thrombin-induced platelet aggregation (Fig. 4) .
DISCUSSION
The main findings of the present study were that ASA, clopidogrel, ticagrelor, and prasugrel pre-treatment improved cardiac function, reduced cardiac fibrosis, decreased infiltration of inflammatory cells into the myocardium after MI, in cases where reperfusion therapy was not performed, and inhibited platelet aggregation under oxidative stress.
In China, morbidity and mortality from AMI are increasing year by year. In the past two decades, the death rate of coronary heart disease in China has doubled to 1 million per year [12] . However, the provision of coronary reperfusion therapy varies greatly in patients with AMI. The China PEACE-Retrospective Acute Myocardial Infarction Study [13] showed that the proportion of patients who did not receive reperfusion was 44.8% in 2001 and 45.0% in 2011. The China AMI (CAMI) registry [14] showed that among patients with non-STEMI, 9.3% received an early invasive approach. Among patients with STEMI, only 43.0% were treated with primary PCI; besides, 9.9% received thrombolytic therapy. In many other developing countries this phenomenon may even be less optimistic. Recanalization with PCI and thrombolytic therapy are not always available, and other approaches have been taken to limit damage caused by MI. The clinical benefits of ASA, clopidogrel, ticagrelor, and prasugrel in STEMI patients undergoing reperfusion therapy have been previously confirmed in clinical trials [6, 15, 16] . Brener et al. [8] showed that pretreatment with ASA for 5-7 days reduced mortality at 30 days among patients with acute coronary syndromes; all patients accepted revascularization within 72 h. Manjyot et al. [17] recently reported that pretreatment with ticagrelor protected against ischemia-reperfusion injury and limited the infarct size in rats. At present, primary prevention by aspirin is highly controversial. Sanmuganathan et al. [18] showed that ASA treatment for primary prevention is safe and worthwhile at coronary event risk ≥ 1.5%/year, safe but of limited value at coronary risk 1%/year, and unsafe at coronary event risk 0.5%/year. Raju et al. [19] suggested that ASA prevents death, MI, and ischemic stroke. Moreover, it would help reduce hemorrhagic stroke as well as major bleeding when used in the primary prevention of cardiovascular disease. However, as shown in a recent research, Aspirin in Reducing Events in the Elderly (ASPREE) trial [20] [21] [22] , the use of aspirin in healthy elderly people who did not have known cardiovascular disease failed to prolong disability-free survival but led to a higher rate of major hemorrhage than placebo, which suggests that the use of ASA is not reasonable for primary prevention. In conjunction with the results of the present study, it was believed that primary prevention with antiplatelet drugs may bring significant clinical benefits for people with high risk factors of MI as well as for those who are not able to receive reperfusion therapy in time. In particular, the use of aspirin will let the economically underdeveloped countries become key beneficiaries, as aspirin does have a cost advantage and is easy to obtain.
In the current study, the cardiac function after an MI was significantly preserved on antiplatelet pre-treatment compared with that in the post-treatment and control groups. These results suggest a mechanism for reduction in 30-day mortality reported in previous studies [8] . Clopidogrel was less effective than ASA, ticagrelor, and prasugrel with regard to improving the LVEF and LVFS in mice in each of the treated groups. The dosage of each drug was based on human clinical dosage. Because different medications showed similar platelet inhibition, differences in the improvement of cardiac function with the use of the four drugs suggests that the protective effects might occur through mechanisms other than platelet inhibition.
Vilahuret et al. [23] suggested that ticagrelor, but not clopidogrel, exerted cardioprotective effects via adenosine-dependent mechanisms.
The adult cardiomyocyte has a limited capacity to regenerate after injury, and 11 the reparative scarring process after MI is critical for maintaining the structural integrity of the ventricular wall. Reparative scarring is followed by remodeling of the surrounding myocardium and eventually leads to impaired cardiac function [11] . It was reported [29] that activated platelets participate in the recruitment and activation of white blood cells in injured areas, release a large number of cytokines and tissue repair factors, and promote the occurrence of inflammatory response in injured areas, while the latter promotes the process of myocardial fibrosis. Antiplatelet drugs can effectively inhibit activation or aggregation of platelets, thus reducing the degree of myocardial fibrosis after MI. Some studies [24, 25] An intense inflammatory response is triggered after MI, which has been implicated in the pathogenesis of post-infarction remodeling and heart failure [26] .
The activated platelets not only bind to different subsets of leukocytes, but also secrete mediators that induce transendothelial migration [27] . In the present study, decreased infiltration of inflammatory cells was observed after MI in the ASA, clopidogrel, ticagrelor, and prasugrel treatment groups compared with that in the control group, especially in those mice pretreated with antiplatelet drugs.
When MI occurs, ROS are acutely produced in an ischemic microenvironment [28] and are major mediators of distal embolization, microvascular obstruction, and inflammatory response [30] . It was reported [31] that H2O2 alone does not affect platelet aggregation. H2O2 dose-dependently promotes low-level thrombin-induced human platelet aggregation. To simulate oxidative stress after MI, platelets were incubated with H2O2. The effects of ASA, clopidogrel, ticagrelor, and prasugrel on platelet aggregation under oxidative stress was investigated in this study. Results
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herein showed that platelet aggregation, stimulated with H2O2, was inhibited significantly by these four drugs. These results suggest that inhibition of platelet activity was associated with limiting myocardial fibrosis and reducing inflammatory cell infiltration, thereby improving cardiac function.
Limitations of the study
There are several limitations of the present study. Firstly, the cardiac function was evaluated on the seventh day after MI, and therefore, there is a need for evaluating long-term effects of pretreatment with these drugs. Secondly, the European Society of Cardiology states that assessment in large animal models is an obligatory step before initiating human trials; thus, results of the current study should be verified in other animal models. Finally, the elucidation of mechanisms responsible for the improvement in cardiac function using these drugs need further investigations.
CONCLUSIONS
Pretreatment with ASA, clopidogrel, ticagrelor, and prasugrel can improve the cardiac function after MI. Pretreatment with these agents may reduce harm caused by MI in patients not receiving reperfusion therapy. 
